Histone deacetylase inhibitors in the treatment of myeloid malignancies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F15%3A00011428" target="_blank" >RIV/00023736:_____/15:00011428 - isvavai.cz</a>
Result on the web
<a href="https://www.novapublishers.com/catalog/product_info.php?products_id=54027&osCsid=" target="_blank" >https://www.novapublishers.com/catalog/product_info.php?products_id=54027&osCsid=</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Histone deacetylase inhibitors in the treatment of myeloid malignancies
Original language description
A number of clinical trials have studied the safety and clinical activity of HDACIs in acute myeloid leukemia and myelodysplastic syndrome. The conclusion of these studies with HDACI as a single agent was that the best use of these compounds would be in combination with other anti-leukemia agents.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Histone deacetylase inhibitors (HDIs): pharmacology, uses and health effects
ISBN
978-1-63482-379-1
Number of pages of the result
30
Pages from-to
63-92
Number of pages of the book
120
Publisher name
Nova Science
Place of publication
New York
UT code for WoS chapter
—